Xtant Medical Holdings, Inc.XTNTEarnings & Financial Report
Xtant Medical Holdings, Inc. is a global medical technology company that develops, manufactures and markets orthobiologic products, neurosurgery devices, and regenerative medicine solutions for orthopedic and neurological care providers. It serves patients and medical institutions across North America, Europe and the Asia-Pacific, with core segments covering spinal surgery supplies and bone regeneration products.
Revenue
$35.4M
Gross Profit
$24.3M
Operating Profit
$4.6M
Net Profit
$3.5M
Gross Margin
68.6%
Operating Margin
13.1%
Net Margin
10.0%
YoY Growth
18.3%
EPS
$0.02
Xtant Medical Holdings, Inc. Q2 FY2025 Financial Summary
Xtant Medical Holdings, Inc. reported revenue of $35.4M (up 18.3% YoY) for Q2 FY2025, with a net profit of $3.5M (up 191.9% YoY) (10.0% margin). Cost of goods sold was $11.1M, operating expenses totaled $19.7M.
Key Financial Metrics
| Total Revenue | $35.4M |
|---|---|
| Net Profit | $3.5M |
| Gross Margin | 68.6% |
| Operating Margin | 13.1% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Xtant Medical Holdings, Inc. Q2 FY2025 revenue of $35.4M breaks down across 3 segments, led by Orthobiologics at $19.4M (54.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Orthobiologics | $19.4M | 54.7% |
| Spinal Implant | $11.1M | 31.3% |
| License Revenue | $5.0M | 14.0% |
Xtant Medical Holdings, Inc. Revenue by Segment — Quarterly Trend
Xtant Medical Holdings, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Orthobiologics and Spinal Implant) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Orthobiologics | $18.3M | $17.1M | $19.4M | $18.1M |
| Spinal Implant | $9.4M | $10.6M | $11.1M | $11.2M |
| License Revenue | $4.6M | $5.5M | $5.0M | $3.6M |
Xtant Medical Holdings, Inc. Annual Revenue by Year
Xtant Medical Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $133.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $133.9M |
| 2024 | $117.3M |
| 2023 | $91.3M |
| 2022 | $58.0M |
Xtant Medical Holdings, Inc. Quarterly Revenue & Net Profit History
Xtant Medical Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $32.4M | +2.7% | $57.0K | 0.2% |
| Q3 FY2025 | $33.3M | +19.0% | $1.3M | 3.9% |
| Q2 FY2025 | $35.4M | +18.3% | $3.5M | 10.0% |
| Q1 FY2025 | $32.9M | +18.0% | $58.0K | 0.2% |
| Q4 FY2024 | $31.5M | +12.1% | $-3.2M | -10.0% |
| Q3 FY2024 | $27.9M | +11.7% | $-5.0M | -18.0% |
| Q2 FY2024 | $29.9M | +48.0% | $-3.9M | -12.9% |
| Q1 FY2024 | $27.9M | +55.3% | $-4.4M | -15.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.9M | $29.9M | $27.9M | $31.5M | $32.9M | $35.4M | $33.3M | $32.4M |
| YoY Growth | 55.3% | 48.0% | 11.7% | 12.1% | 18.0% | 18.3% | 19.0% | 2.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $93.9M | $95.6M | $98.9M | $93.8M | $95.8M | $103.5M | $106.3M | $94.1M |
| Liabilities | $46.3M | $50.6M | $53.2M | $50.9M | $52.0M | $55.0M | $55.9M | $43.2M |
| Equity | $47.7M | $45.0M | $45.7M | $43.0M | $43.9M | $48.5M | $50.4M | $51.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.8M | $-5.1M | $-1.7M | $665000 | $1.3M | $1.3M | $4.6M | $5.4M |